Sutro Biopharma, Inc.
STRO
Rank in Stocks
#17235
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the... Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Share Price
$10.61
Last synced: 2026-11-09
Market Cap
$175.93M
Change (1 day)
10.29%
Change (1 year)
30.50%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Sutro Biopharma, Inc. (STRO)
Category
Healthcare
Earnings for Sutro Biopharma, Inc. (STRO)
Earnings in Jun 2026 TTM: $-180.73M
According to Sutro Biopharma, Inc.'s latest financial reports, its current earnings (TTM) are $-180.73M. In 2025 the company earned $-191.18M, an increase over its 2024 earnings of $-225.10M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for Sutro Biopharma, Inc. from 2016 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-180.73M | -5.46% |
| 2025 | $-191.18M | -15.07% |
| 2024 | $-225.10M | 154.06% |
| 2023 | $-88.60M | -24.08% |
| 2022 | $-116.70M | 10.58% |
| 2021 | $-105.54M | 228.49% |
| 2020 | $-32.13M | -42.37% |
| 2019 | $-55.74M | 57.84% |
| 2018 | $-35.32M | 79.38% |
| 2017 | $-19.69M | -1,256.76% |
| 2016 | $1.70M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $4.76B | -2,733.46% |
US
|
|
| $-2.73B | 1,409.97% |
US
|
|
| $-4.02B | 2,122.18% |
AU
|
|
| $2.83B | -1,663.54% |
BE
|
|
| $1.50B | -928.27% |
NL
|
Questions about Sutro Biopharma, Inc.'s net income
What is Sutro Biopharma, Inc.'s net income?
Sutro Biopharma, Inc.'s net income over the last twelve months is $-180.73M, as of Jun 2026.
What was Sutro Biopharma, Inc.'s net income in 2025?
In 2025, Sutro Biopharma, Inc.'s net income was $-191.18M, compared with $-225.10M in 2024.
How has Sutro Biopharma, Inc.'s net income changed since 2020?
From 2020 to 2025, Sutro Biopharma, Inc.'s net income was highest in 2020 ($-32.13M) and lowest in 2024 ($-225.10M).
How does Sutro Biopharma, Inc.'s net income compare with similar companies?
Sutro Biopharma, Inc.'s net income ($-180.73M) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $4.76B.